Level 3: High End Courses
The ESMIT Level 3 Courses represent the advanced level of the ESMIT Learning Line and is based on the knowledge gained during previous Level 1 and Level 2 Courses. The aim of Level 3 is to go beyond the everyday practice into more focused topics but with the same intent to promote multidisciplinary and interactive learning.
ESMIT Level 3 Courses will be addressing topics from the borderland between research and best clinical practice. Therefore, all participants should be inclined to share personal experiences from the individual research and clinical practice.
These High End Courses are held in the EANM Learning Center in Vienna and their duration is two days for a maximum of 12 participants.
As the philosophy of ESMIT is to deliver highly interactive education, the Level 3 Courses contain several presentations and a diversity of interactive sessions. Moderators having completed the ESMIT Faculty Training will stimulate discussions in the audience with the idea that the participants can learn a lot from each other.
In 2018 there will be offered 8 High End Courses. All courses are listed here below.
ESMIT High End Courses 2018
| March 22-23 | Level 3 Brain Tumors | Vienna, Austria |
| June 18-19 | Level 3 Practical Implementation of Clinical Dosimetry in Nucelar Medicine Therapy | Vienna, Austria |
| September 13-14 | Level 3 Management of Thyroid Cancer | Vienna, Austria |
| November 15-16 | Level 3 Radiopharmacy GMP (fully booked) | Vienna, Austria |
| November 22-23 | Level 3 Advanced Approach to Treatment Response Assessment in Oncology (apply NOW!) | Vienna, Austria |
ESMIT High End Courses 2019
| March 7-8 | Level 3 Brain Tumours | Vienna, Austria |
| April 4-5 | Level 3 Post-Operative Skeleton | Vienna, Austria |
| June 6-7 | Level 3 Advanced Features of Quantification | Vienna, Austria |
| June 13-14 | Level 3 Quantification of Myocardial Perfusion | Caen, France |
| November 14-15 | Level 3 Radiopharmacy GMP | Vienna, Austria |
| November 20-21 | Level 3 Advanced Approach to Treatment Response Assessment in Oncology | Vienna, Austria |
We acknowledge HERMES for granting ESMIT special support with the multimodality viewing stations.